PLX 51107

Drug Profile

PLX 51107

Alternative Names: PLX-51107

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Plexxikon
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 15 Sep 2017 MD Anderson Cancer Center and Daiichi Sankyo agree to co-develop PLX 51107 for Acute myeloid leukemia
  • 20 Apr 2016 Pharmacodynamics data from a preclinical study in Uveal melanoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Mar 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Late-stage disease) in USA (unspecified route) (NCT02683395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top